Study identifier:H8O-MC-GWBO
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes
Type 2 Diabetes Mellitus
Phase 3
No
exenatide
All
58
Interventional
20 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Exenatide:Treatment-Emergent Antibody Negative This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks. | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day Other Name: Byetta Other Name: AC2993 Other Name: LY2148568 |
Experimental: Exenatide:Treatment-Emergent Antibody Positive This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks. | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day Other Name: Byetta Other Name: AC2993 Other Name: LY2148568 |